TP53 and acute myeloid leukemia: For example, in contrast to the transcriptomic signature of LSCs from patients with intermediate prognoses, CD34+CD123+CD3−CD19− LSCs harvested from drug-resistant primary AML cells in patients harboring poor-risk prognosis with TP53 alterations (TP53Alt) are enriched for anomalously activated STAT3 transcription factor signaling [126].